NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced that its independent directors approved an equity award under the company’s 2021 Inducement Plan, effective June 24, 2026, as a material inducement for a new employee to join the company. The award, which complies with Nasdaq Listing Rule 5635(c)(4), grants an option to purchase 10,000 shares of common stock at an exercise price of $3.27 per share, the closing price on the grant date.
According to the company, the new hire was not a previous employee or director of NeuroOne. The option has a ten-year term and vests over four years, with 25% vesting on the first anniversary of the grant (June 24, 2027) and the remainder vesting in 12 equal quarterly installments thereafter. Vesting is contingent upon the individual’s continued employment and is subject to acceleration or forfeiture under certain conditions outlined in the option agreement.
Nasdaq Listing Rule 5635(c)(4) requires public disclosure of equity grants that are not made under a stockholder-approved plan, ensuring transparency for investors. This rule is often used for inducement grants to attract key talent, especially in competitive industries like medical technology.
NeuroOne, based in Eden Prairie, Minnesota, focuses on improving surgical care for neurological disorders. The company markets a minimally invasive electrode technology platform with four FDA-cleared product families: Evo® Cortical Electrodes, Evo® sEEG Electrodes, OneRF® Ablation System (for brain), and OneRF® Trigeminal Nerve Ablation System. These products aim to reduce hospitalizations, lower costs, and improve patient outcomes by combining diagnostic and therapeutic functions. NeuroOne is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs.
This inducement grant signals NeuroOne’s commitment to attracting specialized talent to support its growth and innovation in the neurological device market. For leaders in business and technology, this move highlights the importance of equity compensation as a tool for recruiting key personnel in highly regulated industries. The grant’s structure—with a four-year vesting schedule—aligns the new hire’s interests with long-term shareholder value, a common practice in technology and life sciences companies.
Investors and industry observers may view this as a positive step for NeuroOne’s strategic hiring efforts, particularly as the company continues to expand its product portfolio and pursue new indications. The disclosure also underscores the company’s adherence to corporate governance standards, which can enhance investor confidence.
For more information about NeuroOne and its technologies, visit nmtc1.com.
